Literature DB >> 23187735

GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells.

Yunshan Hu1, Hu Y, HongBin Liu, Liu Hb, Richard W Simpson, Simpson Rw, Anthony E Dear, Dear Ae.   

Abstract

The potential atheroprotective effects of glucagon-like peptide-1 (GLP-1), long-acting GLP-1 analogues and inhibitors of the enzyme dipeptidyl peptidase 4 (DPP-4) are currently the subject of intense research. Recent evidence suggests the effects of DPP-IV inhibitors, may, in-part, be mediated by GLP-1 independent molecular mechanisms. In this report we demonstrate that treatment of human vascular endothelial cells with the DPP-IV inhibitor sitagliptin inhibited tumour necrosis factor alpha (TNFα) induction of plasminogen activator inhibitor type-1 (PAI-1), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) mRNA and protein expression and that this effect was observed to be both GLP-1-dependent and independent. Importantly we identify a molecular mechanism involving sitagliptin-mediated attenuation of TNFα-mediated induction of NFκB and orphan nuclear receptor NUR77 mRNA expression, also able to be reproduced, in part, independent of GLP-1. Taken together these observations may serve to provide a molecular explanation, involving transcriptional regulation of gene expression, for recent in vivo studies suggesting DPP-IV inhibitors may have novel, GLP-1 independent, effects in acting to attenuate endothelial cell dysfunction and atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23187735     DOI: 10.1007/s11033-012-2290-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  32 in total

1.  Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation.

Authors:  H B Liu; Y S Hu; R L Medcalf; R W Simpson; A E Dear
Journal:  Biochem Biophys Res Commun       Date:  2005-08-19       Impact factor: 3.575

2.  Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion.

Authors:  M Morigi; S Angioletti; B Imberti; R Donadelli; G Micheletti; M Figliuzzi; A Remuzzi; C Zoja; G Remuzzi
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

Review 3.  Type-2 diabetes mellitus related cardiovascular risk: new options for interventions to reduce risk and treatment goals.

Authors:  F D Richard Hobbs
Journal:  Atheroscler Suppl       Date:  2006-07-05       Impact factor: 3.235

4.  DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.

Authors:  Nga N Ta; Corinne A Schuyler; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

5.  Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.

Authors:  D T Eitzman; R J Westrick; Z Xu; J Tyson; D Ginsburg
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

6.  Signal transduction events induced or affected by inhibition of the catalytic activity of dipeptidyl peptidase IV (DP IV, CD26).

Authors:  T Kähne; D Reinhold; K Neubert; I Born; J Faust; S Ansorge
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

Review 7.  Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Authors:  Nancy A Thornberry; Ann E Weber
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

8.  Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.

Authors:  Baidong Hou; Mesut Eren; Corrie A Painter; Joseph W Covington; John D Dixon; John A Schoenhard; Douglas E Vaughan
Journal:  J Biol Chem       Date:  2004-02-12       Impact factor: 5.157

9.  Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

Authors:  Li-Jun Ma; Su-Li Mao; Kevin L Taylor; Talerngsak Kanjanabuch; YouFei Guan; YaHua Zhang; Nancy J Brown; Larry L Swift; Owen P McGuinness; David H Wasserman; Douglas E Vaughan; Agnes B Fogo
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

10.  Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.

Authors:  Jun Shirakawa; Hideki Fujii; Kei Ohnuma; Koichiro Sato; Yuzuru Ito; Mitsuyo Kaji; Eri Sakamoto; Megumi Koganei; Hajime Sasaki; Yoji Nagashima; Kikuko Amo; Kazutaka Aoki; Chikao Morimoto; Eiji Takeda; Yasuo Terauchi
Journal:  Diabetes       Date:  2011-02-17       Impact factor: 9.461

View more
  9 in total

1.  Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.

Authors:  Sen Shi; Swayam Prakash Srivastava; Megumi Kanasaki; Jianhua He; Munehiro Kitada; Takako Nagai; Kyoko Nitta; Susumu Takagi; Keizo Kanasaki; Daisuke Koya
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

2.  Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways.

Authors:  Song-Tao Tang; Qiu Zhang; Hai-Qin Tang; Chang-Jiang Wang; Huan Su; Qing Zhou; Wei Wei; Hua-Qing Zhu; Yuan Wang
Journal:  Endocrine       Date:  2016-01-12       Impact factor: 3.633

Review 3.  DPP4 Activity, Hyperinsulinemia, and Atherosclerosis.

Authors:  Kaitlin M Love; Zhenqi Liu
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 4.  Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?

Authors:  Wellington Santana da Silva Júnior; Amélio Fernando de Godoy-Matos; Luiz Guilherme Kraemer-Aguiar
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

Review 5.  DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.

Authors:  Jianqiang Zhang; Qiuyue Chen; Jixin Zhong; Chaohong Liu; Bing Zheng; Quan Gong
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

6.  Sitagliptin improves functional recovery via GLP-1R-induced anti-apoptosis and facilitation of axonal regeneration after spinal cord injury.

Authors:  Wen Han; Yao Li; Jiangting Cheng; Jing Zhang; Dingwen Chen; Mingqiao Fang; Guangheng Xiang; Yanqing Wu; Hongyu Zhang; Ke Xu; Hangxiang Wang; Ling Xie; Jian Xiao
Journal:  J Cell Mol Med       Date:  2020-06-22       Impact factor: 5.310

7.  Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction.

Authors:  Paulo R Rizzo Genestreti; Remo H M Furtado; Rocio Salsoso; Talia F Dalçóquio; Andre Franci; Fernando R Menezes; Cesar Caporrino; Aline G Ferrari; Carlos A K Nakashima; Marco A Scanavini Filho; Felipe G Lima; Roberto R C V Giraldez; Luciano M Baracioli; Jose C Nicolau
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

8.  Effects of sitagliptin on ß-adrenoceptor mediated relaxation in streptozotocin-diabetic rat aorta

Authors:  Ayhanım Elif Müderrisoğlu; Betül Rabia Erdoğan; Zeynep Elif Yeşilyurt; Ceren Uyar Boztaş; İrem Karaçömerlioğlu; Vecdi Melih Altan; Ebru Arıoğlu İnan
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

9.  Diabetes pathogenesis and management: the endothelium comes of age.

Authors:  Kaitlin M Love; Eugene J Barrett; Steven K Malin; Jane E B Reusch; Judith G Regensteiner; Zhenqi Liu
Journal:  J Mol Cell Biol       Date:  2021-10-21       Impact factor: 6.216

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.